Vistin Pharma ASA Invites Shareholders to Q3 Earnings Call
Join Vistin Pharma ASA for Their Q3 Conference Call
Vistin Pharma ASA (VISTN), a notable pharmaceutical entity, is gearing up to share its third quarter earnings along with year-to-date results. This event is scheduled for a Friday, setting the stage for insightful updates and discussions.
Details of the Conference Call
On the day of the earnings release, shareholders and interested parties will have the opportunity to participate in a conference call at 08:30 CET. The session aims to facilitate communication between the management team and attendees, concluding with a Q&A segment to answer pressing inquiries.
How to Access the Call
The conference will be conducted in English to ensure accessibility for all participants. Attendees can join via different platforms:
Webcast Access
For those preferring an online experience, a webcast will be available at the following link: https://edge.media-server.com/mmc/p/zojifvb6. This portal will allow viewers to engage with the management's presentation effectively.
Telephone Participation
Listeners preferring audio access can take part through a telephone conference. To register, visit the following link: https://register-conf.media-server.com/register/BI4b6411bcd117427f8df81e59f7b2fd65. This option provides a great alternative to join the earnings discussion.
Contact Information for Inquiries
For any queries prior to the event, you can reach out to Alexander Karlsen, CFO of Vistin Pharma, at +47 97053621 or via email at alexander.karlsen@vistin.com. Alexander is available to provide further clarity about the call and any specific company developments.
About Vistin Pharma
Established in Norway, Vistin Pharma is dedicated to the production of Metformin Hydrochloride (API). The company also manufactures Direct Compressible lubricated granules. As a leading European producer of Metformin, Vistin holds a strong market position, catering to numerous pharmaceutical companies across the continent. Its headquarters are in Oslo, complemented by a specialized manufacturing facility in Kragerø, employing a team of highly qualified personnel.
Frequently Asked Questions
What is the date of the Q3 conference call?
The Q3 conference call will be held on the last Friday of October, coinciding with the earnings release.
How can I participate in the conference call?
You can join via the webcast or telephone conference, both of which are accessible through provided links.
What information will be shared during the call?
Participants can expect discussions on the company's financial performance and updates regarding Metformin production.
Who can I contact for more information?
For additional questions, you can contact Alexander Karlsen, CFO of Vistin Pharma.
Is the conference call open to the public?
Yes, the call is open to all shareholders and interested parties, encouraging broader engagement.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.